Research trends of worldwide ophthalmologic randomized controlled trials in the 21st century: A bibliometric study
- AOPR Vol. 3, Issue 4, Pages: 159-170(2023)
- 作者机构：
1. Department of Ophthalmology, Lanzhou University Second Hospital,Lanzhou,China,730000
2. Medical School of Chinese PLA,Beijing,China,100853
3. Department of Ophthalmology, Chinese PLA General Hospital,Beijing,China,100853
- 作者简介：
- 基金信息：
DOI：10.1016/j.aopr.2023.07.003
CLC：
扫 描 看 全 文
Research trends of worldwide ophthalmologic randomized controlled trials in the 21st century: A bibliometric study. [J]. AOPR 3(4):159-170(2023)
Research trends of worldwide ophthalmologic randomized controlled trials in the 21st century: A bibliometric study. [J]. AOPR 3(4):159-170(2023) DOI： 10.1016/j.aopr.2023.07.003.
摘要
Background,Randomized controlled trials (RCTs) are often considered the gold standard and the cornerstone for clinical practice. However, bibliometric studies on worldwide RCTs of ophthalmology published in the 21st century have not been reported in detail yet. This study aims to perform a bibliometric study and visualization analysis of worldwide ophthalmologic RCTs in the 21st century.,Methods,Global ophthalmologic RCTs from 2000 to 2022 were searched in the Web of Science Core Collection. The number of publications, country/region, institution, author, journal, and research hotspots of RCTs were analyzed using HistCite, VOSviewer, CiteSpace, and Excel software.,Results,2366 institutions and 90 journals from 83 countries/regions participated in the publication of 1769 global ophthalmologic RCTs, with the United States leading in the number of volumes and research field, and the Moorfields Eye Hospital contributing to the most publications. Ophthalmology received the greatest number of publications and co-citations. Jeffrey S. Heier owned the most publications and Jost B. Jonas owned the most co-citations. The knowledge foundations of global ophthalmologic RCTs were mainly retinopathy, glaucoma, dry eye disease (DED), and cataracts, and anti-vascular endothelial growth factor (VEGF) therapy (ranibizumab), topical ocular hypotensive medication, laser trabeculoplasty. Anti-VEGF therapy for age-related macular degeneration (AMD), DME (diabetic macular edema), and DED, the use of new diagnostic tools, and myopia were the hottest research highlights. Anti-VEGF therapy, prompt laser, triamcinolone, and verteporfin photodynamic therapy for AMD, DME, and CNV (choroidal neovascularization), DED, myopia, and open-angle glaucoma were the research hotspots with the longest duration. The future research hotspots might be DED and the prevention and control of myopia.,Conclusions,Overall, the number of global ophthalmologic RCTs in the 21st century was keeping growing, there was an imbalance between the regions and institutions, and more efforts are required to raise the quantity, quality, and global impact of high-quality clinical evidence in developing countries/regions.
Abstract
Background,Randomized controlled trials (RCTs) are often considered the gold standard and the cornerstone for clinical practice. However, bibliometric studies on worldwide RCTs of ophthalmology published in the 21st century have not been reported in detail yet. This study aims to perform a bibliometric study and visualization analysis of worldwide ophthalmologic RCTs in the 21st century.,Methods,Global ophthalmologic RCTs from 2000 to 2022 were searched in the Web of Science Core Collection. The number of publications, country/region, institution, author, journal, and research hotspots of RCTs were analyzed using HistCite, VOSviewer, CiteSpace, and Excel software.,Results,2366 institutions and 90 journals from 83 countries/regions participated in the publication of 1769 global ophthalmologic RCTs, with the United States leading in the number of volumes and research field, and the Moorfields Eye Hospital contributing to the most publications. Ophthalmology received the greatest number of publications and co-citations. Jeffrey S. Heier owned the most publications and Jost B. Jonas owned the most co-citations. The knowledge foundations of global ophthalmologic RCTs were mainly retinopathy, glaucoma, dry eye disease (DED), and cataracts, and anti-vascular endothelial growth factor (VEGF) therapy (ranibizumab), topical ocular hypotensive medication, laser trabeculoplasty. Anti-VEGF therapy for age-related macular degeneration (AMD), DME (diabetic macular edema), and DED, the use of new diagnostic tools, and myopia were the hottest research highlights. Anti-VEGF therapy, prompt laser, triamcinolone, and verteporfin photodynamic therapy for AMD, DME, and CNV (choroidal neovascularization), DED, myopia, and open-angle glaucoma were the research hotspots with the longest duration. The future research hotspots might be DED and the prevention and control of myopia.,Conclusions,Overall, the number of global ophthalmologic RCTs in the 21st century was keeping growing, there was an imbalance between the regions and institutions, and more efforts are required to raise the quantity, quality, and global impact of high-quality clinical evidence in developing countries/regions.
关键词
OphthalmologyRandomized controlled trials (RCTs)The 21st centuryWorldwideBibliometricResearch trends
Keywords
OphthalmologyRandomized controlled trials (RCTs)The 21st centuryWorldwideBibliometricResearch trends
references
1 Evidence-based medicineA new approach to teaching the practice of medicine Jama. Nov 4, 268 (17) (1992), pp. 2420-2425, 10.1001/jama.1992.03490170092032
2 D.L. Sackett, W.M. Rosenberg, J.A. Gray, R.B. Haynes, W.S. RichardsonEvidence based medicine: what it is and what it isn't BMJ (Clinical research ed)., 312 (7023) (Jan 13 1996), pp. 71-72, 10.1136/bmj.312.7023.71
3 K.F. Schulz, D.G. Altman, D. MoherCONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ (Clinical research ed) Mar, 340 (23) (2010), p. c332, 10.1136/bmj.c332
4 K.D. Bojikian, D. Gupta, J.M. Dettori, et al.Evidence in ophthalmology: are we doing better? Ophthalmology, 122 (12) (Dec 2015), pp. 2584-2586, 10.1016/j.ophtha.2015.06.012
5 S.A. AlRyalat, A. Abukahel, K.A. ElubousRandomized controlled trials in ophthalmology: a bibliometric study F1000Research, 8 (2019), p. 1718, 10.12688/f1000research.20673.1
6 C. Lu, X. Li, K. YangTrends in shared decision-making studies from 2009 to 2018: a bibliometric analysis Frontiers in public health, 7 (2019), p. 384, 10.3389/fpubh.2019.00384
7 Y. Xiao, H. Wu, G. Wang, H. MeiMapping the worldwide trends on energy poverty research: a bibliometric analysis (1999-2019) International journal of environmental research and public health (4) (Feb 11 2021), p. 18, 10.3390/ijerph18041764
8 D. Gu, J. Li, X. Li, C. LiangVisualizing the knowledge structure and evolution of big data research in healthcare informatics. International journal of medical informatics Feb, 98 (2017), pp. 22-32, 10.1016/j.ijmedinf.2016.11.006
9 E. Garfield, S.W. Paris, W.G. StockHistCite: a software tool for informetric analysis of citation linkage NFD Information-Wissenschaft und Praxis, 57 (8) (2006), pp. 391-400
10 E.L. WaltmanSoftware survey: VOSviewer, a computer program for bibliometric mapping Scientometrics, 84 (Aug. 2010), pp. 523-538, 10.1007/s11192-009-0146-3
11 C.M. ChenCiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature Journal of the American Society for Information Science and Technology, 57 (3) (Feb 1 2006), pp. 359-377, 10.1002/asi.20317
12 H. Wang, L.-X. Ke, C.-C. Lu, W. Li, Y.-M. ZhaoResearch trends of uveal melanoma: a bibliometric study and visualization analysis TMR cancer, 4 (2) (2021)
13 P.J. Rosenfeld, D.M. Brown, J.S. Heier, et al.1 Ranibizumab for neovascular age-related macular degeneration The New England journal of medicine, 355 (14) (Oct 5 2006), pp. 1419-1431, 10.1056/NEJMoa054481
14 M.A. Kass, D.K. Heuer, E.J. Higginbotham, et al.2 the ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Archives of Ophthalmology, 120 (6) (2002), pp. 701-713, 10.1001/archopht.120.6.701
15 PC VV3 the Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators American journal of ophthalmology, 130 (4) (Oct 2000), pp. 429-440, 10.1016/s0002-9394(00)00538-9
16 A. Heijl, M.C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, M. Hussein4 Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial Archives of ophthalmology (Chicago, Ill, 120 (10) (Oct 2002), pp. 1268-1279, 10.1001/archopht.120.10.1268 1960
17 R.M. Schiffman, M.D. Christianson, G. Jacobsen, J.D. Hirsch, B.L. Reis5 reliability and validity of the ocular surface disease Index Archives of ophthalmology (Chicago, Ill, 118 (5) (May 2000), pp. 615-621, 10.1001/archopht.118.5.615 1960
18 A P.6 photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1 early treatment diabetic retinopathy study research group Archives of Ophthalmology, 103 (12) (1985), pp. 1796-1806, 10.1001/archopht.1985.01050120030015
19 D.M. Brown, P.K. Kaiser, M. Michels, et al.7 Ranibizumab versus verteporfin for neovascular age-related macular degeneration The New England journal of medicine, 355 (14) (Oct 5 2006), pp. 1432-1444, 10.1056/NEJMoa062655
20 L.T. Chylack Jr., J.K. Wolfe, D.M. Singer, et al.8 the lens Opacities classification system III. The longitudinal study of cataract study group Archives of ophthalmology (Chicago, Ill : 1960), 111 (6) (Jun 1993), pp. 831-836, 10.1001/archopht.1993.01090060119035
21 M.J. Elman, L.P. Aiello, R.W. Beck, et al.9 Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology. Jun, 117 (6) (2010), pp. 1064-1077.e35, 10.1016/j.ophtha.2010.02.031
22 NM B10 Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group Archives of ophthalmology (Chicago, Ill : 1960), 117 (10) (Oct 1999), pp. 1329-1345, 10.1001/archopht.117.10.1329
23 J.P. Craig, K.K. Nichols, E.K. Akpek, et al.2 TFOS DEWS II definition and classification report The ocular surface, 15 (3) (Jul 2017), pp. 276-283, 10.1016/j.jtos.2017.05.008
24 L. Jones, L.E. Downie, D. Korb, et al.3 TFOS DEWS II management and therapy report The ocular surface, 15 (3) (Jul 2017), pp. 575-628, 10.1016/j.jtos.2017.05.006
25 Q.D. Nguyen, D.M. Brown, D.M. Marcus, et al.6 Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology, 119 (4) (Apr 2012), pp. 789-801, 10.1016/j.ophtha.2011.12.039
26 N.M. Bressler7 Evaluating new retinal imaging techniques Archives of ophthalmology (Chicago, Ill, 116 (4) (Apr 1998), pp. 521-522, 10.1001/archopht.116.4.521 1960
27 F. Stapleton, M. Alves, V.Y. Bunya, et al.8 TFOS DEWS II epidemiology report The ocular surface, 15 (3) (Jul 2017), pp. 334-365, 10.1016/j.jtos.2017.05.003
28 A.J. Bron, C.S. de Paiva, S.K. Chauhan, et al.9 TFOS DEWS II pathophysiology report The ocular surface, 15 (3) (Jul 2017), pp. 438-510, 10.1016/j.jtos.2017.05.011
29 J.C. Yam, Y. Jiang, S.M. Tang, et al.10 low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control Ophthalmology, 126 (1) (Jan 2019), pp. 113-124, 10.1016/j.ophtha.2018.05.029
30 Group BmtoA-RMDWPTS1 photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2 Archives of Ophthalmology, 119 (2) (2001), pp. 198-207 10-1001/pubs.Ophthalmol.-ISSN-0003-9950-119-2-ecs00156
31 E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr., M. Feinsod, D.R. Guyer9 Pegaptanib for neovascular age-related macular degeneration The New England journal of medicine, 351 (27) (Dec 30 2004), pp. 2805-2816, 10.1056/NEJMoa042760
32 B.A. Holden, T.R. Fricke, D.A. Wilson, et al.10 global prevalence of myopia and high myopia and temporal trends from 2000 through 2050 Ophthalmology, 123 (5) (May 2016), pp. 1036-1042, 10.1016/j.ophtha.2016.01.006
33 J. Huang, D. Wen, Q. Wang, et al.11 efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis Ophthalmology. Apr, 123 (4) (2016), pp. 697-708, 10.1016/j.ophtha.2015.11.010
34 M.S.I. 13A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema Ophthalmology. Sep, 115 (9) (2008), pp. 1447-1449, 10.1016/j.ophtha.2008.06.015 1449.e1-10
35 J.J. Walline, K.L. Greiner, M.E. McVey, L.A. Jones-Jordan14 Multifocal contact lens myopia control Optometry and vision science, 90 (11) (Nov 2013), pp. 1207-1214, 10.1097/opx.0000000000000036 official publication of the American Academy of Optometry
36 E.T. Cunningham Jr., A.P. Adamis, M. Altaweel, et al.15 A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology, 112 (10) (Oct 2005), pp. 1747-1757, 10.1016/j.ophtha.2005.06.007
37 P. Mitchell, F. Bandello, U. Schmidt-Erfurth, et al.16 the RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology. Apr, 118 (4) (2011), pp. 615-625, 10.1016/j.ophtha.2011.01.031
38 N.S. Anstice, J.R. Phillips17 Effect of dual-focus soft contact lens wear on axial myopia progression in children Ophthalmology. Jun, 118 (6) (2011), pp. 1152-1161, 10.1016/j.ophtha.2010.10.035
39 J.F. Arevalo, J. Fromow-Guerra, H. Quiroz-Mercado, et al.18 Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up Ophthalmology, 114 (4) (Apr 2007), pp. 743-750, 10.1016/j.ophtha.2006.12.028
40 P. Massin, F. Audren, B. Haouchine, et al.19 Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial Ophthalmology. Feb, 111 (2) (2004), pp. 218-224, 10.1016/j.ophtha.2003.05.037 discussion 224-5
41 D.F. Garway-Heath, D.P. Crabb, C. Bunce, et al.20 Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial Lancet (London, England), 385 (9975) (Apr 4 2015), pp. 1295-1304, 10.1016/s0140-6736(14)62111-5
42 M. Michaelides, A. Kaines, R.D. Hamilton, et al.21 A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2 Ophthalmology, 117 (6) (Jun 2010), pp. 1078-1086.e2, 10.1016/j.ophtha.2010.03.045
43 D.F. Martin, M.G. Maguire, S.L. Fine, et al.22 Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology. Jul, 119 (7) (2012), pp. 1388-1398, 10.1016/j.ophtha.2012.03.053
44 J.S. Wolffsohn, R. Arita, R. Chalmers, et al.1 TFOS DEWS II diagnostic methodology report The ocular surface, 15 (3) (Jul 2017), pp. 539-574, 10.1016/j.jtos.2017.05.001
45 A. Chia, Q.S. Lu, D. Tan3 five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops Ophthalmology. Feb, 123 (2) (2016), pp. 391-399, 10.1016/j.ophtha.2015.07.004
46 D. Minckler, Editor-in-ChiefEvidence-based ophthalmology series and content-based continuing medical education for the journal Ophthalmology, 107 (1) (2000), pp. 0-10
47 L. de Souza Leão, G. EyalThe rise of randomized controlled trials (RCTs) in international development in historical perspective Theory and Society, 48 (3) (2019/06/01 2019), pp. 383-418, 10.1007/s11186-019-09352-6
48 A.C. Fanaroff, R.M. Califf, R.D. LopesHigh-quality evidence to inform clinical practice Lancet (London, England), 394 (10199) (Aug 24 2019), pp. 633-634, 10.1016/s0140-6736(19)31256-5
49 M. Rahman, T. FukuiBiomedical research productivity: factors across the countries. International journal of technology assessment in health care Winter, 19 (1) (2003), pp. 249-252, 10.1017/s0266462303000229
50 F.L. Lin, M.C. WangLongevity and economic growth in China and India using a newly developed bootstrap ARDL model Frontiers in public health, 8 (2020), p. 291, 10.3389/fpubh.2020.00291
51 W. Luo, Y. XieEconomic growth, income inequality and life expectancy in China Social science & medicine, 256 (1982), Article 113046, 10.1016/j.socscimed.2020.113046 Jul 2020
52 Q. Wang, J.A. Tapia GranadosEconomic growth and mental health in 21st century China Social science & medicine, 220 (1982), pp. 387-395, 10.1016/j.socscimed.2018.11.031 Jan 2019
53 L.M. Weng, Y.L. Zheng, M.S. Peng, T.T. Chang, B. Wu, X.Q. Wang A Bibliometric Analysis of Nonspecific Low Back Pain Research, 2020, Pain research & management (2020), Article 5396734, 10.1155/2020/5396734
54 T. Xu, B. Wang, H. Liu, et al.Prevalence and causes of vision loss in China from 1990 to 2019: findings from the global burden of disease study 2019 The Lancet Public health, 5 (12) (Dec 2020), pp. e682-e691, 10.1016/s2468-2667(20)30254-1
55 W.L. Wong, X. Su, X. Li, et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. The Lancet Global health Feb, 2 (2) (2014), pp. e106-e116, 10.1016/s2214-109x(13)70145-1
56 Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study The Lancet Global health. Feb, 9 (2) (2021), pp. e130-e143, 10.1016/s2214-109x(20)30425-3
57 Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. The Lancet Global health Feb, 9 (2) (2021), pp. e144-e160, 10.1016/s2214-109x(20)30489-7
58 V. PrasadWhy randomized controlled trials are needed to accept new practices: 2 medical worldviews Mayo Clinic proceedings, 88 (10) (Oct 2013), pp. 1046-1050, 10.1016/j.mayocp.2013.04.026
59 E.S. Caplan, A.S. KesselheimAnti-VEGF therapy in ophthalmology: a qualitative analysis of transformative drug development Drug discovery today, 21 (6) (Jun 2016), pp. 1019-1026, 10.1016/j.drudis.2016.05.001
60 P.S. Mettu, M.J. Allingham, S.W. CousinsIncomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities Progress in retinal and eye research, 82 (May 2021), Article 100906, 10.1016/j.preteyeres.2020.100906
61 C.D. Jhaveri, A.R. Glassman, F.L. Ferris 3rd, et al.Aflibercept monotherapy or bevacizumab first for diabetic macular edema The New England journal of medicine, 387 (8) (Aug 25 2022), pp. 692-703, 10.1056/NEJMoa2204225
62 R. Dana, J. Meunier, J.T. Markowitz, C. Joseph, C. SiffelPatient-reported burden of dry eye disease in the United States: results of an online cross-sectional survey American journal of ophthalmology, 216 (Aug 2020), pp. 7-17, 10.1016/j.ajo.2020.03.044
63 J. Vehof, H. Snieder, N. Jansonius, C.J. HammondPrevalence and risk factors of dry eye in 79,866 participants of the population-based Lifelines cohort study in The Netherlands. The ocular surface Jan, 19 (2021), pp. 83-93, 10.1016/j.jtos.2020.04.005
64 D.A. Schaumberg, J.J. Nichols, E.B. Papas, L. Tong, M. Uchino, K.K. NicholsThe international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Investigative ophthalmology & visual science Mar, 52 (4) (2011), pp. 1994-2005, 10.1167/iovs.10-6997e
65 S. Amano, K. InoueEstimation of prevalence of meibomian gland dysfunction in Japan Cornea. Jun, 36 (6) (2017), pp. 684-688, 10.1097/ico.0000000000001208
66 B.A. Holden, T.R. Fricke, D.A. Wilson, et al.Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050 Ophthalmology, 123 (5) (May 2016), pp. 1036-1042, 10.1016/j.ophtha.2016.01.006
67 S.N. Ali Momin, R. SiddiquiMask-associated dry-eye in COVID-19 pandemic: a case report and review of the literature JPMA The Journal of the Pakistan Medical Association, 72 (5) (May 2022), pp. 981-982, 10.47391/jpma.4157
68 P.C. Gupta, M.P. Kumar, J. RamCOVID-19 pandemic from an ophthalmology point of view The Indian journal of medical research, 151 (5) (May 2020), pp. 411-418, 10.4103/ijmr.IJMR_1369_20
69 S. BarabinoA narrative review of current understanding and classification of dry eye disease with new insights on the impact of dry eye during the COVID-19 pandemic. Ophthalmology and therapy Sep, 10 (3) (2021), pp. 495-507, 10.1007/s40123-021-00373-y
70 J. Wang, Y. Li, D.C. Musch, et al.Progression of myopia in school-aged children after COVID-19 home confinement JAMA ophthalmology. Mar, 139 (3) (2021), pp. 293-300, 10.1001/jamaophthalmol.2020.6239 1
71 X. Zhang, S.S.L. Cheung, H.N. Chan, et al.Myopia incidence and lifestyle changes among school children during the COVID-19 pandemic: a population-based prospective study The British journal of ophthalmology (Aug 2 2021), 10.1136/bjophthalmol-2021-319307
72 J. Kan, M. Wang, Y. Liu, et al.A novel botanical formula improves eye fatigue and dry eye: a randomized, double-blind, placebo-controlled study The American journal of clinical nutrition, 112 (2) (Aug 1 2020), pp. 334-342, 10.1093/ajcn/nqaa139
73 H. Wang, J. Zhou, Y. Li, et al.Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis Therapeutic advances in neurological disorders, 14 (2021), Article 17562864211056710, 10.1177/17562864211056710
74 X. Huang, X. Fan, J. Ying, S. ChenEmerging trends and research foci in gastrointestinal microbiome Journal of translational medicine, 17 (1) (Feb 28 2019), p. 67, 10.1186/s12967-019-1810-x
75 L. Shen, S. Wang, W. Dai, Z. ZhangDetecting the interdisciplinary nature and topic hotspots of robotics in surgery: social network analysis and bibliometric study Journal of medical Internet research, 21 (3) (2019), Article e12625, 10.2196/12625 Mar 26
0
Views
0
下载量
0
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.